Similar articles

• A short-term double-blind controlled trial of prenazone (DA 2370) in rheumatoid arthritis.

  Rooney PJ, Watkins C, Ahola SJ, Gray GI, Dick WC. Rooney PJ, et al. Curr Med Res Opin. 1974;2(1):43-50. doi: 10.1185/03007997409111740. Curr Med Res Opin. 1974. PMID: 4276368 Clinical Trial. No abstract available.
• Absorption and distribution of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA2370) in the rat.

  Coppi G, Vidi A, Gallazzi A, Perego R. Coppi G, et al. Arzneimittelforschung. 1974 May;24(5):801-2. Arzneimittelforschung. 1974. PMID: 4408147 No abstract available.
• Clinical and laboratory evaluation of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in rheumatoid arthritis and ankylosing spondylitis.

  Lignière GC, Colombo B, Carrabba M, Ferrari P, Robotti E. Lignière GC, et al. Arzneimittelforschung. 1972 Jan;22(1):Suppl 1a:253-8. Arzneimittelforschung. 1972. PMID: 4553232 Clinical Trial. No abstract available.
• [Current possibilities in the antiphlogistic and immunosuppressive therapy of progressive chronic polyarthritis].

  Tanner E, Klotz L, Seidel K. Tanner E, et al. Beitr Rheumatol. 1971;16:143-72. Beitr Rheumatol. 1971. PMID: 4946260 Review. German. No abstract available.
• [Passage of nonsteroidal anti-inflammatory agents across the synovial membrane].

  Netter P, Bannwarth B, Monot C, Royer RJ, Gaucher A. Netter P, et al. Presse Med. 1983 Sep 24;12(33):2049-52. Presse Med. 1983. PMID: 6226020 Review. French.